This company has been acquired
Amedisys (AMED) Stock Overview
Provides healthcare services in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
AMED Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Amedisys, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$100.99 |
| 52 Week High | US$101.02 |
| 52 Week Low | US$82.15 |
| Beta | 0.90 |
| 1 Month Change | 3.57% |
| 3 Month Change | 6.73% |
| 1 Year Change | 2.58% |
| 3 Year Change | -16.02% |
| 5 Year Change | -57.69% |
| Change since IPO | 1,823.61% |
Recent News & Updates
Why Amedisys, Inc. (NASDAQ:AMED) Could Be Worth Watching
Aug 14
Amedisys: Thoughts On UnitedHealth Merger, Plus Underlying Factors
Aug 04There's Reason For Concern Over Amedisys, Inc.'s (NASDAQ:AMED) Price
Jun 11Recent updates
Why Amedisys, Inc. (NASDAQ:AMED) Could Be Worth Watching
Aug 14Amedisys: Thoughts On UnitedHealth Merger, Plus Underlying Factors
Aug 04There's Reason For Concern Over Amedisys, Inc.'s (NASDAQ:AMED) Price
Jun 11Final Push For Amedisys As UnitedHealth Awaits Regulatory Clearance
Nov 05Is Amedisys, Inc. (NASDAQ:AMED) Trading At A 41% Discount?
Apr 10Does Amedisys (NASDAQ:AMED) Have A Healthy Balance Sheet?
Feb 25Amedisys (NASDAQ:AMED) Will Be Hoping To Turn Its Returns On Capital Around
Feb 10At US$83.54, Is It Time To Put Amedisys, Inc. (NASDAQ:AMED) On Your Watch List?
Jan 03A Look At The Fair Value Of Amedisys, Inc. (NASDAQ:AMED)
Dec 16Capital Allocation Trends At Amedisys (NASDAQ:AMED) Aren't Ideal
Nov 12Is Now The Time To Look At Buying Amedisys, Inc. (NASDAQ:AMED)?
Sep 19An Intrinsic Calculation For Amedisys, Inc. (NASDAQ:AMED) Suggests It's 38% Undervalued
Sep 04Amedisys: ROIC, Tangible Book Value Each Softening
Aug 24Slowing Rates Of Return At Amedisys (NASDAQ:AMED) Leave Little Room For Excitement
Aug 04Amedisys profit beats by $0.24, revenue misses by $25.23M, 2022 guidance below estimates
Jul 27We Think Amedisys (NASDAQ:AMED) Can Stay On Top Of Its Debt
Jul 20At US$115, Is It Time To Put Amedisys, Inc. (NASDAQ:AMED) On Your Watch List?
Jun 04Returns On Capital At Amedisys (NASDAQ:AMED) Have Stalled
May 05Is Amedisys, Inc. (NASDAQ:AMED) Trading At A 40% Discount?
Apr 20Does Amedisys (NASDAQ:AMED) Deserve A Spot On Your Watchlist?
Apr 06Is Amedisys (NASDAQ:AMED) A Risky Investment?
Feb 20Amedisys (NASDAQ:AMED) Shareholders Will Want The ROCE Trajectory To Continue
Jan 19Should You Be Adding Amedisys (NASDAQ:AMED) To Your Watchlist Today?
Dec 03These 4 Measures Indicate That Amedisys (NASDAQ:AMED) Is Using Debt Safely
Nov 18Amedisys (NASDAQ:AMED) Could Easily Take On More Debt
Aug 18Calculating The Fair Value Of Amedisys, Inc. (NASDAQ:AMED)
Jul 23Amedisys: Strategic Contessa Acquisition Underpins The Home Healthcare Growth Opportunity
Jul 18Shareholder Returns
| AMED | US Healthcare | US Market | |
|---|---|---|---|
| 7D | 0.1% | 0.6% | -1.0% |
| 1Y | 2.6% | -9.6% | 14.9% |
Return vs Industry: AMED exceeded the US Healthcare industry which returned -31% over the past year.
Return vs Market: AMED underperformed the US Market which returned 19.4% over the past year.
Price Volatility
| AMED volatility | |
|---|---|
| AMED Average Weekly Movement | 1.5% |
| Healthcare Industry Average Movement | 6.8% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: AMED has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: AMED's weekly volatility (1%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1982 | 19,000 | Richard Ashworth | www.amedisys.com |
Amedisys, Inc., together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.
Amedisys, Inc. Fundamentals Summary
| AMED fundamental statistics | |
|---|---|
| Market cap | US$3.32b |
| Earnings (TTM) | US$85.63m |
| Revenue (TTM) | US$2.40b |
Is AMED overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AMED income statement (TTM) | |
|---|---|
| Revenue | US$2.40b |
| Cost of Revenue | US$1.36b |
| Gross Profit | US$1.04b |
| Other Expenses | US$952.04m |
| Earnings | US$85.63m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 2.60 |
| Gross Margin | 43.19% |
| Net Profit Margin | 3.56% |
| Debt/Equity Ratio | 26.4% |
How did AMED perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/08/14 20:42 |
| End of Day Share Price | 2025/08/14 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Amedisys, Inc. is covered by 16 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Matthew Gillmor | Baird |
| Steven Valiquette | Barclays |
| Sarah James | Barclays |